Freedom of Information request on number of people who have received the Astra Zeneca Vaccine and have reported a blood clot following the vaccination (FOI 21-337)
Published 28 June 2021
© Crown copyright 2021
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/publications/freedom-of-information-responses-from-the-mhra-week-commencing-3-may-2021/freedom-of-information-request-on-number-of-people-who-have-received-the-astra-zeneca-vaccine-and-have-reported-a-blood-clot-following-the-vaccination
4th May 2021 FOI 21/337
Thank you for your FOI request dated 1 st April 2021, whereby you requested:
“the number of people who have received the Astra Zeneca Vaccine and have reported a blood clot following the vaccination.”
The MHRA is collecting data concerning any adverse reactions observed to vaccine treatment through our Yellow Card Scheme. We are regularly publishing Yellow Card data associated with COVID-19 vaccinations. Yellow Card data for drugs is routinely published on the Yellow Card website, with vaccine data available on request. However, for COVID-19 vaccinations we are proactively publishing details of adverse drug reactions received, including MHRA assessment of the data to provide context. Please note this data is updated weekly. https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-reactions
You may also wish to refer to the MHRA’s press release relating to this issue: https://www.gov.uk/government/news/mhra-issues-new-advice-concluding-a-possible-link-between-covid-19-vaccine-astrazeneca-and-extremely-rare-unlikely-to-occur-blood-clots
Yours sincerely, FOI Team Vigilance and Risk Management of Medicines Division